[Seite 104↓]

Literaturverzeichnis

1. Ghanaati Z et al.: Endocrinological and genetic findings in patients with polycystic ovary syndrome, Neuroendocrinology Letters, 1999, 20 299

2. Jacobs HS.: Polycystic ovaries and polycystic ovary syndrome, Gyn Endocrin 1987, 1, 113

3. Dewailly D et al.: Definition, clinical manifestations and prevalence of PCOS, In: Androgen excess disorders in women, edited by Azziz et al., Lippincott- Raven Publishers, Philadelphia, 1997

4. Dunaif et al.In: Current issues in endocrinology and metabolism, polycystic ovary syndrome. Blackwell Scientific Publications, Boston, 1992

5. Ovesen PG et al. Polycystic ovary syndrome II. Endocrinology and metabolism, Ugeskr Laeger, 1998, 160, 265

6. Barnes RB et al. The polycystic ovary syndrome: Pathogenesis and treatment, Ann Intern Med, 1989, 110, 386

7. Adams et al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone, Lancet, 1985, 1375

8. Burger CW et al. Pulsatile luteinizing hormone patterns in the follicular phase of the menstrual cycle, polycystic ovarien disease (PCOD) and non- PCOD secondary amenorrhea, J Clin Endocrinol Metab, 1985, 61, 1126

9. Carmina E., Prevalence of adrenal androgen excess in PCOS, In: Androgen excess disorders in women, edited by Azziz et al., Lippincott- Raven Publishers, Philadelphia, 1997

10. Turner E., Investigations of adrenal function in women with oligomenorrhea and hirsutism (clinical PCOS) from the north- east of England using adrenal stimulation test, Clin Endocrinol, 1992, 36, 389

11. Polson DW et al., The distribution of oestradiol in plasma in relation to uterine cross-sectional area in women with polycystic or multifollicular ovaries, Clin Endocrinol (Oxf), 1987, 26, 581

12. Lanzone A et al., Insulin secretion in polycystic ovarian disease: effect of ovarian suppression by GnRH agonist, Hum Reprod, 1990, 5, 143

13. Carmina E et al, The contribution of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome, Hum Reprod, 1999, 14, 307

14. Rouru J et al., Serum leptin concentrations in women with polycystic ovary syndrome, J Clin Endocrinol Metab, 1997, 82, 1697

15. Wild RA et al., The influence of body weight on lipoprotein lipids in patients with polycystic ovary syndrome, Am J Obstet Gynecol, 1988, 159, 423

16. Barnes RB., The pathgenesis of polycystic ovary syndrome: lessons from ovarian stimulation studies, J Endocrinol Invest, 1998, 21, 567

17. Fauser BC., Observations in favor of normal early follicle development and disturbed dominant follicle selection in polycystic ovary syndrome, Gynecol Endocrinol, 1994, 8, 75

18. Azziz R., Abnormalities of Adrenocortical Steroidogenesis in PCOS, In: Androgen excess disorders in women, edited by Azziz et al., Lippincott- Raven Publishers, Philadelphia, 1997

19. Nestler JE, Insulin and ovarian androgen excess, In: Androgen excess disorders in women, edited by Azziz et al., Lippincott- Raven Publishers, Philadelphia, 1997

20. Cara JF, Insulin-like growth factors, insulin- like growth factor binding proteins and ovarian androgen production, Horm Res, 1994, 42, 49

21. Anttila L et al., Polycystic ovaries in women with gestational diabetes, Obstet Gynecol, 1998, 92, 13


[Seite 105↓]

22. Nestler JE et al, Decreases in ovarian cytochrom P450c17a activity and serum free testosteron after reduction in insulin secretion in women with polycystic ovary syndrome, N Engl J Med, 1996, 335, 617

23. Buyalos RP et al., The influence of luteinizing hormone and insulin on sex steroids and sex- hormon binding globulin in polycystic ovarian syndrome, Fertil Steril, 1993, 60, 626

24. Dahlgren et al., Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective study of women, Acta Obstet Gynecol Scand, 1992, 71, 599

25. Holte J et al., Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: A sign of a pre- hypertensive state?, Hum Reprod, 1996, 11, 23

26. Dahlgren et al, Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long term follow- up focusing on natural history and circulating hormones , Fertil Steril, 1992, 57, 505

27. Farhi DC et al, Endometrial adenocarcinoma in women under 25 years of age, Obstet Gynecol, 1986, 68, 741

28. Escobedo LG et al, Infertility- associated endometrial cancer risk may be limited to specific subgroups of infertile women, Obstet Gynecol, 1991, 77, 124

29. Schildkraut JM et al, Epithelial ovarian cancer risk among women with polycystic ovary syndrome, Obstet Gynecol, 1996, 88, 554

30. Urman B et al, Pregnancy in infertile PCOD patients. Complications and outcome, J Reprod Med, 1997, 42, 501

31. Zalel Y et al, Spontaneous ovarian hyperstimulation syndrome concomitant with spontaneous pregnancy in a woman with polycystic ovary syndrome, Am J Obstet Gynecol, 1992, 167, 122

32. Bassil S et al, Ovarian Hyperstimulation Syndrome: A Review, Assisted Reprod Reviews, 1995, 5, 90

33. Ludwig M et al, Überblick über das ovarielle Überstimulationssyndrom: ein reproduktionsmedizinisch- iatrogenes Krankheitsbild mit internistischer Konsequenz, WMW, 1997, 22, 516

34. Hurwitz A et al, Early unwinding of torsion of an ovarian cyst as an result of hyperstimulation syndrome, Fertil Steril, 1983, 40, 393

35. Schenker JG et al, Complications of assisted reproductive techniques, Fertil Steril, 1994, 61, 411

36. Winkler J et al, Acute decline in renal function as a consequence of ovarian hyperstimulation syndrome, Nephron, 1992, 60, 104

37. Bornstein R et al, Ovarian hyperstimulation syndrome after different treatment schedules, Int J Fertil, 1981, 26, 279

38. Balasch J et al, Acute prerenal failure and liver dysfunction in a patient with severe ovarian hyperstimulation syndrome, Hum Reprod, 1990, 5, 348

39. Dahl Lyons CA et al, Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors, Hum Repro, 1994, 9, 792

40. Delbaere A et al, Angiotensin II immunoreactivity is elevated in ascites during severe ovarian hyperstimulation syndrome: implications for pathophysiology and clinical management, Fertil Steril, 1994, 62, 731

41. WHO, Agents stimulating gonadal function in human, World Health Organ Tech Rep Ser, p. 514

42. Risk B et al, Modern management of ovarian hyperstimulation syndrome, Human Reprod, 1991, 6, 1082

43. Navot D et al, Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and traetment, Fertil Steril, 1992, 58, 249


[Seite 106↓]

44. Dale PO et al, In vitro fertilization in infertile women with the polycystic ovary syndrome, Human Reprod, 1991, 6, 238

45. Smitz J et al, Incidence of severe ovarian hyperstimulation syndrome after GnRH agonist/ HMG superovulation for in- vitro- fertilization, Hum Reprod, 1990, 5, 933

46. Navot D et al, Risk factors and prognostic variables in the ovarian hyperstimulation syndrome, Fertil Steril, 1987, 48, 57

47. Goldsman MP et al, Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome, Fertil Steril, 1995, 63, 268

48. Schenker JG, Clinical aspects of the ovarian hyperstimulation syndrome, Eur J Obstet Gynecol Reprod Biol, 1999, 85, 13

49. Mac Dougall MJ et al, In –vitro fertilization and the ovarian hyperstimulation syndrome, Hum Reprod, 1992, 7, 597

50. Mac Dougall MJ et al, A controlled study compairing patients with and without polycystic ovaries undergoing in-vitro fertilization, Hum Reprod, 1993, 8, 233

51. Prader A, Zachmann M., Das adrenogenitale Syndrom

52. Speiser PW et al, High frequency of nonclassical steroid 21- hydroxylase deficiency, Am J Hum Genet, 1985, 37, 650

53. Dewailly D et al, Pathophysiology and clinical manifestations of nonclassic 21-hydroxylase deficiency. In: Androgen excess disorders in women, edited by Azziz et al., Lippincott Raven Publishers, Philadelphia, 1997

54 . Dewailly D, Clinical and biological phenotypes in late-onset 21-hydroxylase deficiency, J Clin Endocrinnol Metab, 1986, 63, 418

55. Azziz R et al, Diagnosis, screening and treatment of nonclassic 21-hydroxylase deficiency. In: Androgen excess disorders in women, edited by Azziz et al., Lippincott- Raven Publishers, Philadelphia, 1997

56. Fiet J et al, The application of a new highly sensitive radioimmunoassay for plasma 21-deoxycortisol to the detection of steroid 21-hydroxylase deficiency, Ann Clin Biochem, 1994, 31, 56

57. Witchel SF et al, Identification of heterozygotic carriers of 21- hydroxylase deficiency: sensitivity of ACTH stimulation tests, Am J Med Genet, 1998, 76, 337

58. White PC et al, Structure of human steroid 21- hydroxylase genes, Proc Natl Acad Sci USA, 1986; 83, 5111

59. Higashi Y et al, Complete nucleotid sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosomes: a pseudogene and a genuin gene, Proc Natl Acad Sci USA, 1986, 83, 2841

60. White PC et al, Two genes encoding steroid 21-hydroxylase are located near the genes encoding the forth component of complement in man, Proc Natl Acad Sci USA, 1985, 82, 1089

61 . Fiet J et al, Comparison of basal and adrenocortcotropin- stimulated plasma 21- deoxycortisol and 17- hydroxyprogesterone values as biological markers of late- onset adrenal hyperplasia, J Clin Endocrinol Metab, 1988, 66, 659

62. Miller SA et al, A simple salting out procedure for extracting DNA from human nucleated cells, Nucl Acids Res, 1987, 16, 1988

63. White MB et al, Detecting single base substitutions as heteroduplex polymorphisms, Genomics, 1992, 12, 301

64. Tusie-Luna MT et al, A mutation (Pro 30 to Leu) in CYP21 represents a potential nonclassic steroid 21-hydroxylase deficiency allel, Mol Endocrinol, 1991, 5, 685


[Seite 107↓]

65. Higashi Y et al, Aberrant splicing and missense mutations cause steroid 21-hydroxylase P450 (C21) deficiency in humans: Possible gene conversion products, Proc Natl Acad Sci USA, 1988, 85, 7486

66. Speiser PW et al, Molecular genetic analysis of nonclassic steroid 21-hydroxylase deficiency associated with HLA-B14 DR1, N Engl J Med, 1988, 319, 19

67. Dolzan V et al, Adrenal 21-hydroxylasegene mutations in Slovenian hyperandrogenic women: evaluation of corticotrophin stimulation and HLA polymorphisms in screening for carrier status, Eur J Endocrin, 1999, 141, 132

68. Ibanez L et al, Ovarian 17- hydroxyprogesterone hyperresponsiveness to gonadotropine releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropine stimulation testing, J Clin Endocrinol Metab, 1996, 81, 4103

69. Steck T et al, Response of gonadotropins to pituitary stimulation with luteinizing hormone releasing hormone is a more specific than sensitive parameter for the polycystic ovary syndrome, Gynecol Endocrinol, 1991, 5, 235

70. Urbanek M et al, Thirty- seven candidate genes for polycystic ovary syndrome: Strongest evidence for linkage is with follistatin, Proc Natl Acad Sci USA, 1999, 96, 8573

71. Rosenfield RL, Ovarian and adrenal function in polycystic ovary syndrome, Endocrinol Metab Clin North Am, 1999, 28, 265

72. Gonzales F, Adrenal involvement in Polycystic Ovary Syndrome, Semin Reprod Endocrinol, 1997, 15, 137

73. Fruzetti F et al, Ovarian influence on adrenal androgen secretion in women with polycystic ovary syndrome, Fertil Steril, 1995, 63, 734

74. Fortunati N, Sex hormone- binding globulin: not only a transport protein, What news is around the corner?, J Endocrinol Invest, 1999, 22, 223

75. Azziz R et al, Effect of obesity on the response to acute adrenocorticotropin stimulation in eumenorrheic women, Fertil Steril, 1991, 56, 427

76. Arroyo A et al, Inappropriate gonadotropin secretion in polycystic ovary syndrom: influence of adiposity, J Clin Endocrin Metab, 1997, 82, 3728

77. Gustafson O et al, Androstendione as a predictor of ovarian hyperstimulation syndrome, Hum Reprod, 1992, 7, 918

78 . Franks S., Polycystic ovary syndrome: a changing perspective. Review, Clin Endocrinol, 1989, 31, 87

79. Ciampelli M et al, Insulin and polycystic ovary syndrome: a new look at an old subject. Review, Gynecol Endocrinol, 1998, 12, 277

80. Sierra-Honigmann MR et al, Biological action of leptin as an angiogenic factor, Science, 1998, 281, 1683

81. Chahab F et al, Corrections of the sterility defect in homocygous obese female mice by treatment with the human recombinant leptin, Nat Genet, 1996, 12, 318

82. Stephens TW et al, The role of neuropeptide Y in the antiobesity action of the obese gene product, Nature, 1995, 377, 530

83. Nahum R et al, Metabolic regulation of androgen production by human theka cells in vitro, Hum Reprod, 1995, 10, 75

84. Plagemann A et al, Observations on the orexigenic hypothalamic neuropeptide Y-system in neonatally overfed weanling rats, J Neuroendocrinol, 1999, 11, 541

85. Sir-Petermann T et al, Are circulating leptin and luteinizing hormone synchronizrd in patients with polycystic ovary syndrome, Hum Reprod, 1999, 14, 1435


[Seite 108↓]

86. Palmert MR et al, The impact of revesible gonadal sex steroid suppression on serum leptin concentrations in children with central precocious puberty, J Clin Endocrinol Metab, 1998, 83, 1091

87. Considene RV et al, Serum immunoreactive leptin concentrations in normal weight and obese humans, N Engl J Med, 1996, 334, 292

88. Caro JF, Leptin is normal in PCOS; an editorial about three negative papers, J Clin Endocrin Metab, 1997, 82, 1685

89. Brzechffa PR et al, Serum immunoreactive leptin concentrations in women with polycystic ovary syndrome, J Clin Endocrin metab, 1996, 81, 4166

90. Sinha MK et al, Clinical aspects of leptin, Vitam Horm, 1998, 54, 1

91. Krassas GE et al, Leptin levels in women with polycystic ovary syndrome before and after treatment with diazoxid , Eur J Endocrinol, 1998, 139, 184

92 . Laughlin GA et al, Serum leptin levels in women with polycystic ovary syndrome: the role of insulin resistence/ hyperinsulinemia, J Clin Endocrin Metab, 1997, 82, 1692

93. Ciaraldi TP et al, Cellular insulin resistance in adipocytesfrom obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity, J Clin Endocrin Metab, 1997, 82, 1421

94. Grinspoon S et al, Serum leptin levels in women with anorexia nervosa, J Clin Endocrinol Metab, 1996, 81, 3861

95. Cohen B et al, Modulation of insulin activities by leptin, Science 1996, 274, 1185

96. Behre HM et al, Strong association between serum levels of leptin and testosterone in men, J Clin Endocrinol Oxf, 1997, 47, 237

97. Geisthovel F et al, C-peptide and insulin, but not C19- steroids, support the predictive value of body mass index on leptin in serum of premenopausal women, Hum Reprod, 1998, 13, 547

98. Cioffi JA et al, The expression of leptin and its receptors in pre-ovulatory human follicles, Mol Hum Reprod, 1997, 3, 467

99. Karlsson C et al, Expression of functional leptin receptors in the human ovary, J Clin Endocrin Metab, 1997, 82, 4144

100. De Clue TJ et al, Insulin resistance and hyperinsulinemia induce hyperandrogenism in a young type B insulin resistant female, J Clin Endocrinol Metab, 1991, 72, 1308

101. Nestler JE et al, Suppression of serum insulin by diazoxide does not alter serum testosterone or sex hormone binding globulin levels in healthy nonobese women, Am J Obstet Gynecol, 1990, 163, 1243

102. Barbieri RL, Hyperandrogenism, insulin resistence and acanthosis nigricans. 10 years of progress, J Reprod Med, 1994, 39, 327

103. Willis D et al, Modulation by insulin of follicle stimulating hormone and luteinizing hormone actions in human granulosa of normal and polycystic ovaries, J Clin Endocrinol Metab, 1996, 81, 302

104. Meirow D et al, Insulin resistant and non- resistant polycystic ovary syndrome represent two clinical and endocrinological subgroups, Hum Reprod, 1995, 10, 1951

105. Carmina E et al, Altered regulation of insulin like growth factor binding protein-1 in patients with polycystic ovary syndrome, J Soc Gynecol Investig, 1995, 2, 743

106. Cornwalls CM et al, Foolicular fluid renin concentration and IVF outcome, Hum Reprod, 1990, 5, 413

107. Morris RS et al, Prorenin is elevated in polycystic ovary syndrome and may reflect hyperandrogenism, Fertil Steril, 1995, 64, 1099


[Seite 109↓]

108. Jaatinen TA et al, Serum total renin is elevated in women with polycystic ovary syndrome, Fertil Steril, 1995, 63, 1000

109. Jasper M et al, Immunreactive interleukin-1 beta and tumor necrosis factor- alpha in thecal, stromal and granulosa cell cultures from normal and polycystic ovaries, Hum Reprod, 1995, 10, 1352

110. Orvieto R et al, Interleukin-2 production by cultured human granulosa cells, Int J Fertil Womens Med, 1997, 42, 297

111. Neulen J et al, Human Chorionic Gonadotropin – dependent expression of Vascular endothelial growth factor/ Vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome, J Clin Endocrinol Metab, 1995, 80, 1967

112. Agrawal R et al, Serum vascular endothelial growth factor concentrations and Doppler blood flow velocities in in vitro fertilization: relevance to ovarian hyperstimulation syndrome and polycystic ovaries, Fertil Steril, 1998, 70, 651

113. Anasti JN et al, Human follicle fluid vascular endothelial growth factor concentrations are correlated with luteinization in spontaneously developing follicles, Hum Repro, 1998, 13, 1144

114. Punglia RS et al, Regulation of vascular endithelial growth factor expression by insulin- like growth factor I, Diabetes, 1997, 46, 1619

115. Akagi Y et al, Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor I, Cancer Res, 1998, 58, 4008

116. Joseph IB et al, Androgenes regulate vascular endothelial growth factor content in normal and malignant prostatic tissue, Clin Cancer Res, 1997, 3, 2507

117. Hague W et al, Non-mendelian segregation ratios in familial polycystic ovaries. (Abstract), 7th Int Cong Hum Genet Berlin, 1986, 277

118. Lunde O et al, Familial Clustering in the Polycystic Ovarian Syndrome, Gynecol Obstet Invest, 1989, 28, 23

119. Nelson VL et al, Augmented androgen production is a stable steroidogenic phenotype of propagated theca cellsfrom plycystic ovaries, Mol Endocrin, 1999 in press

120. Kahsar-Miller M et al, The Development of the Polycystic Ovary Syndrome: Family History as a risk Factor, TEM, 1998, 9, 55

121. Jahanfar S et al, A twin study of polycystic ovary syndrome, Fertil Steril, 1995, 63, 478

122. Gilling-Smith C et al, Hypersecretion of androstendione by isolated theca cells from polycystic ovaries, J Clin Endocrinol Metab, 1994, 79, 1158

123. Carey AH et al, Polycystic ovaries and premature male pattern baldness are associated with one allel of the steroid metabolism gene CYP17, Hum Mol Genet, 1994, 3, 1873

124. Tetchatraisak K et al, Frequency of a polymorphism in the regulatory region of the 17alpha-Hydroxylase-17,20-Lyase (CYP17) in hyperandrogenic states, Clin Endocrin, 1997, 46, 131

125. Gharani N et al, Association of the steroid synthesis gene CYP11alpha with polycystic ovary syndrome and hyperandrogenism, Hum Mol Genet, 1997, 6, 397

126. Conway GS et al, The tyrosine kinase domain of the insulin receptor gene is normal in women with hyperinsulinaemia and polycystic ovary syndrome, Hum Reprod, 1994, 9, 1681

127. Talbot JA et al, Molecular scanning of the insulin receptor gene in women with polycystic ovary syndrome, J Clin Endocrinol Metab, 1996, 81, 1979

128. Bennett ST et al, Susceptibility to human typ I diabetes at IDDM 2 is determined by tandem repeat variation at the insulin gene minisatellite locus, Nat Genet, 1995, 9, 284

129. Waterworth DM et al, Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome, Lancet, 1997, 349, 986


[Seite 110↓]

130. Urbanek M et al, Allelic variants of follistatin gene in polycystic ovary syndrome, J Clin Endocrin Metab, 2000, 85 (12), 4455

131. Urbanek M et al, Thirty- seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin, Proc Natl Acad Sci USA, 1999, 96, 8573

132. Witchel SF et al, Candidate gene analysis in premature pubarche and adolescent hyperandrogenism, Fertil Steril, 2001, 75, 724

133. Morel Y et al, Clinical and molecular Hum genetics of congenital adrenal hyperplasia due to 21-hydroxylase deficiency, Adv Genet, 1991, 20, 1

134. Morel Y et al, Molecular genetics of the congenital adrenal hyperplasia. Cellular and molecular biology of the adrenal cortex, 1992; pp 222: 123

135. Schulze E et al, Allele-dropout using PCR-based diagnosis for the splicing mutation in intron-2 of the CYP21B-gene: successful amplification with a taq/Pwo-polymerase mixture, Endocr-Res, 1998, 24 (3-4), 637

136. Kobayashi H et al, Evolutionary origine of mutations in the primate cytochrome P45021 gene, Am J Hum Genet, 1992, 50, 766

137. Miller WL, Gene conversions, deletions and polymorphisms in congenital adrenal hyperplasia, Am J Hum Genet, 1988, 42, 4

138. Higashi Y et al, Evidence for frequent gene conversion in the steroid 21-hydroxylase P450 (C21)gene: Implications for steroid 21-hydroxylase deficiency, Am J Hum Genet, 1988, 42, 17

139. Amor M et al, A mutation in the CYP21B gene (Ile-172 to Asn) causes steroid 21-hydroxylase deficiency, Proc Natl Acad Sci USA, 1988, 85, 1600

140. Globerman H et al, A nonsense mutation causing steroid 21-hydroxylase deficiency, L Clin Invest, 1988, 82, 139

141. Chiou SH et al, A missense mutation at Ile172 to Asn or Arg356 to Trp causes steroid 21-hydroxylase deficiency, J Biol Chem, 1990, 265, 3549

142. Rodrigues NR et al, Molecular characterisation of the HLA-linked steroid 21-hydroxylase B gene from an individual with congenital adrenal hyperplasia, EMBO J, 1987, 6, 1653

143. Higashi Y et al, Effects of individual mutations in the P450(C21) pseudogen on the P450 (C21) activity and their distribution in the patient genomes of congenital steroid 21-hydroxylase deficiency, J Biochem, 1991, 109, 638

144. Wedell A et al, Steroid 21-hydroxylase deficiency: Three additional mutated allels and establishment of phenotype-genotype relationships of common mutations, Proc Natl Acad Sci USA, 1992, 89, 7232

145. Helmberg A et al, R338H and P453S: CYP21 mutations associated with nonclassic steroid deficiency that are not apparent gene conversions, Mol Endocrinol, 1992, 6, 1318

146. Helmberg A., Twin genes and endocrine disease: CYP21 and CYP11B genes, Acta Endocrinol, 1993, 129, 97

147. Azziz R et al, Molecular abnormalities of the 21-hydroxylase gene in hyperandrogenic women with an exaggerated 17alpha-hydroxyprogesterone response to short- term adrenal stimulation, Am J Obstet Gynecol, 1995, 172, 914

148. Knochenhauer ES et al, Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism, J Clin Endocrinol Metab, 1997, 82, 479

149. Dörner G et al, Genetic and environmental effects on sexual brain organization mediated by sex hormones, International Behavioral Development Symposium 2000 in Minot State University, North Dakota, May 2000

150. Owerbach D et al, Direct analysis of CYP21B genes in 21-hydroxylase deficiency using polymerase chain reaction amplification, Mol Endocrinol, 1990, 4 (1), 125


[Seite 111↓]

151. Helmberg A et al, Identification of molecular defects causing congenital adrenal hyperplasiaby cloning and differential hybridization of polymerase chain reaction- amplified 21-hydroxylase (CYP21)genes, DNA-Cell-Biol, 1992, 11 (5), 359

152. Dörner G, Umwelthormone als Ursache lebenslanger Fehlfunktionen, Humboldt Spektrum, 1996, 4, 12


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 3.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
11.02.2004